Zydus Lifesciences Gets USFDA Nod for Scopolamine Transdermal System
August 30, 2024 16:13
Zydus Lifesciences receives USFDA approval to market Scopolamine transdermal system for nausea and vomiting prevention. This is the fifth ANDA approval for Zydus in the transdermal portfolio.